Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Balmer

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Vaccine|July 3, 2021
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 monthsLars Østergaard, Timo Vesikari, Shelly D Senders, et al.
Infectious Diseases and Therapy|July 24, 2020
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 StudiesJohannes Beeslaar, Judith Absalon, Annaliesa S Anderson, et al.
Infection and Immunity|July 25, 2006
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacJamie Findlow, Stephen Taylor, Audun Aase, et al.
The Lancet. Child & Adolescent Health|June 18, 2026
Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trialLars Ostergaard, Hanna Czajka, Lilia Roque-Guerrero, et al.
Plos One|March 5, 2026
Meningococcal carriage and transmission dynamics in college students in Louisville, KentuckyForest W Arnold, Leslie Wolf Parrish, Subathra Marimuthu, et al.
The Lancet. Infectious Diseases|May 3, 2026
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort studyAmanda C Miles, Jelena Vojicic, Paula Peyrani, et al.
Emerging Infectious Diseases|July 5, 2008
A prospective study of etiology of childhood acute bacterial meningitis, TurkeyMehmet Ceyhan, Inci Yildirim, Paul Balmer, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Vaccine|July 3, 2021
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 monthsLars Østergaard, Timo Vesikari, Shelly D Senders, et al.
Infectious Diseases and Therapy|July 24, 2020
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 StudiesJohannes Beeslaar, Judith Absalon, Annaliesa S Anderson, et al.
Infection and Immunity|July 25, 2006
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacJamie Findlow, Stephen Taylor, Audun Aase, et al.
The Lancet. Child & Adolescent Health|June 18, 2026
Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trialLars Ostergaard, Hanna Czajka, Lilia Roque-Guerrero, et al.
Plos One|March 5, 2026
Meningococcal carriage and transmission dynamics in college students in Louisville, KentuckyForest W Arnold, Leslie Wolf Parrish, Subathra Marimuthu, et al.
The Lancet. Infectious Diseases|May 3, 2026
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort studyAmanda C Miles, Jelena Vojicic, Paula Peyrani, et al.
Emerging Infectious Diseases|July 5, 2008
A prospective study of etiology of childhood acute bacterial meningitis, TurkeyMehmet Ceyhan, Inci Yildirim, Paul Balmer, et al.
Pageof 8